SEC Form 4
------------

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 193 or Section 30(h) of the Investment Company Act of 1940	4 hours per response: 0.5				
1. Name and Address of Reporting Person* Ares Trading S.A.	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>PRECIGEN, INC.</u> [ PGEN ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner				
(Last) (First) (Middle) RUE DE L'OURIETTE 151 ZONE INDUSTRIELLE DE L'OURIETTAZ	3. Date of Earliest Transaction (Month/Day/Year) 09/03/2021	<ul> <li>Officer (give title Other (specify below)</li> <li>below)</li> </ul>				
ZONE INDUSTRIELLE DE L'OURIETTAZ	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)		X Form filed by One Reporting Person				
AUBONNE V8 1170		Form filed by More than One Reporting Person				
(City) (State) (Zip)						

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Date, Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	09/03/2021		<b>S</b> <sup>(1)</sup>		29,065	D	\$6.4169	21,193,911	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned         (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deriv Secu Acqu (A) o Dispe of (D	erivative ecurities cquired A) or isposed f (D) nstr. 3, 4		Ind 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

## Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Ares Trading, S.A. on April 29, 2021.

## Remarks:

This Form 4 is being filed by each of the following persons (together, the Reporting Persons): Ares Trading SA, the direct beneficial owner of the shares, Merck Serono SA, Aubonne, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany, an indirect beneficial owner of the shares, and Merck KGaA, Darmstadt, Germany, an indirect beneficial owner of the shares, and Merck KGaA, Darmstadt, Germany, an indirect beneficial owner of the shares, and Merck KGaA, Darmstadt, Germany, an indirect beneficial owner of the shares, and Merck KGaA, Darmstadt, Germany, an indirect beneficial owner of the shares of Merck KGaA, Darmstadt, Germany, and indirect beneficial owner of the shares, and Merck KGaA, Darmstadt, Germany. Merck Serono SA, Aubonne, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany. Merck Serono SA, Aubonne, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany. Merck KGaA, Darmstadt, Germany is a publicly traded company (Frankfurt Stock Exchange, DAX 30) and the beneficiary of the two companies.

<u>/s/ Cedric Hyde, Authorized</u> <u>Signatory of Merck Serono</u> <u>SA</u>	<u>09/08/2021</u>
<u>/s/ Florence Jolidon,</u> <u>Authorized Signatory of</u> <u>Merck Serono SA</u>	<u>09/08/2021</u>
<u>/s/ Cedric Hyde, Authorized</u> <u>Signatory of Ares Trading SA</u>	<u>09/08/2021</u>
<u>/s/ Tearaboth Te, Authorized</u> <u>Signatory of Ares Trading SA</u>	<u>09/08/2021</u>
<u>/s/ Andreas Stickler,</u> <u>Authorized Signatory of</u> <u>Merck KGaA</u>	<u>09/08/2021</u>
<u>/s/ Tobias Greven, Authorized</u> <u>Signatory of Merck KGaA</u>	<u>09/08/2021</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.